In Entwicklung
Wissenschaft·27.04.2026KI-Zusammenfassung
Intellia's CRISPR Treatment Shows 87% Reduction in Hereditary Angioedema Attacks
Intellia Therapeutics' CRISPR-based treatment for hereditary angioedema met its goals in a Phase 3 trial, reducing attacks by 87% compared with placebo. The one-time infusion therapy edits genes directly in the liver and achieved 62% of patients being attack-free six months after treatment. The company has started a rolling FDA application and plans to launch in the first half of next year if approved.
C
CNBC